This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Teva Provides 2014 Financial Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provides its current outlook for non-GAAP financial performance for the full year ending December 31, 2014.

In an effort to enhance investor understanding of the business performance of the company, and to provide more clarity and transparency regarding its projections for 2014, given the significant uncertainty concerning possible generic competition to Copaxone ® in the U.S., the Company is providing two alternative scenarios for its current non-GAAP financial outlook for the year:
  • the "Generic Copaxone" scenario assumes the launch of at least two AP-rated generic competitors to Copaxone ® in the U.S. on June 1, 2014; and
  • the "Exclusive Copaxone" scenario assumes no generic competition to Copaxone ® in the U.S. during 2014.

Both scenarios assume the launch of Copaxone ® 40mg three-times-a-week in early 2014 and exclusive sales of the generic version of Pulmicort ® in the U.S. throughout 2014. The outlook provided is organic, and neither alternative includes the potential impact of any business development activities.

Below is a table summarizing the non-GAAP financial outlook for the two scenarios:
  Generic   Exclusive
Copaxone Copaxone
Net Revenues ($ b) 19.3-20.3 19.8-20.8
GP (%) 57%-59% 58%-60%
R&D ($ b) 1.3-1.45 1.3-1.45
S&M ($ b) 4.0-4.1 4.0-4.1
G&A ($ b) 1.2 1.2
OP ($ b) 4.8-5.1 5.35-5.65
Finance Expenses ($ m) 310-350 310-350
Tax (%) 20%-21% 19%-20%
Number of Shares (m) 840-850 840-850
EPS ($) 4.20-4.50 4.80-5.10
Cash Flow from Operations ($ b)


Teva estimates that each month of delay in the launch of generic competitors to Copaxone ® in the U.S. will contribute on average approximately $78 million to net revenues and $0.08 to non-GAAP diluted earnings per share.

“2014 will be a pivotal year for Teva and a year of major transitions across the company", stated Eyal Desheh, Acting President and CEO of Teva. "We will continue to make significant progress in implementing our strategy. We will focus our efforts on our generics business and core R&D programs, including high-value complex generics, promising specialty medicines and New Therapeutic Entities. In our specialty business, we anticipate six important launches and the potential submission of ten additional medicines for approval. At the same time, we are focused on increasing our organizational effectiveness through our cost reduction program to ensure Teva’s leadership position, growth and sustainable profitability.”

Detailed financial outlook:
  • Net Revenues:
Generic Exclusive
Copaxone Copaxone
U.S. $ in billions
Generics inc. API 9.8 - 10.5 9.8 - 10.5
Specialty: 7.3 - 7.7 7.8 - 8.2
OTC & Other*: 2.0 - 2.2 2.0 - 2.2
Total Net Revenues 19.3 - 20.3 19.8 - 20.8

*Including OTC, distribution & other
  • Net Revenues by Geographies:
Generic Exclusive
Copaxone Copaxone
U.S. $ in billions
United States 9.5-9.9 10.0-10.4
Europe*: 5.7-6.2 5.7-6.2
Rest of the World: 3.8-4.2 3.8-4.2
Total Net Revenues 19.3 - 20.3 19.8 - 20.8

*All members of the European Union, Switzerland, Norway and certain South Eastern Europe countries
  • Generics (including API) Net Revenues:
  U.S. $ in billions
United States 4.1 - 4.5
Europe*: 3.1 - 3.5
Rest of the World: 2.3 - 2.6
Total Generics Net Revenues 9.8 - 10.5

*All members of the European Union, Switzerland, Norway and certain South Eastern Europe countries
  • Key Specialty Medicines Net Revenues:*All members of the European Union, Switzerland, Norway and certain South Eastern Europe countries
  Generic   Exclusive
Copaxone Copaxone
U.S. $ in millions
Copaxone® 3,100-3,200 3,600-3,700
Treanda® 750
ProAir® 510
Azilect® 390
Qvar® 380
Nuvigil® 350
  • Other net revenues of $2.0-$2.2 billion, which include net revenues from Teva's share in PGT Healthcare, our joint venture with Procter & Gamble, of $1.0-1.1 billion, and approximately $0.2 billion of OTC contract manufacturing in the U.S.Overall in-market revenues of PGT Healthcare will be approximately $1.7 billion. This amount represents sales of the combined OTC portfolios of Teva and P&G outside of North America.
  • Profit margins:
    Other   Generic   Exclusive   OTC &
Generics   Specialty   Copaxone   Copaxone   Other
Total Revenues ($ b) 9.8-10.5 4.2-4.5 3.1-3.2 3.6-3.7 2.0-2.2
GP (%) 41%-44% 83%-85% 88%-91% 88%-91% 32%-34%
R&D ($ b) 0.45-0.50 0.8-0.9 0.1 0.1 -
Total S&M ($ b) 1.7-1.8 1.4 0.6-0.7 0.6-0.7 0.3
OP before G&A ($ b) 2.0-2.3 1.15-1.55 2.0-2.1 2.55-2.65 0.35-0.5
% of Teva Total OP before G&A* 33% 21% - 39% 7%

* Mid-range compared to "Exclusive Copaxone" scenario (approximate)

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs